CG Oncology Bladder Cancer Therapy Cuts Recurrence 68%

Phase 3 trial results for cretostimogene, an engineered virus immunotherapy, were announced on Monday.

Updated on Nov. 16, 2026 in Cancer

Bold flat-color vector editorial illustration of a single glass vial and a coiled clear tube on a teal surface, evoking a targeted bladder cancer treatment.
CG Oncology reported Phase 3 results on Monday showing its engineered bladder cancer immunotherapy cretostimogene cut tumor recurrence risk by 68% in 367 patients. AI Illustration. Upload story photo >

CG Oncology announced positive Phase 3 results for cretostimogene, a cancer immunotherapy for bladder cancer, reporting a 68% reduction in tumor recurrence risk compared to current medical practice. The randomized study enrolled 367 patients with intermediate-risk bladder cancer.

Why it matters

Recurrence is a central challenge in managing bladder cancer, and repeated surgeries can eventually cost patients bladder function. A treatment that substantially lowers recurrence risk could change how intermediate-risk patients are managed after surgical removal.

The Phase 3 randomized trial enrolled 367 patients with intermediate-risk bladder cancer and reported a 68% reduction in tumor recurrence risk relative to current medical practice. The source does not disclose absolute recurrence rates per arm or the duration of patient follow-up.

The players

CG Oncology

CG Oncology is a biopharmaceutical company developing cretostimogene, an oncolytic immunotherapy for bladder cancer.

The details

Cretostimogene is a cancer immunotherapy made from a common cold virus engineered to target cells expressing a specific bladder tumor mutation. Physicians infuse it directly into the bladder through a catheter, where the virus enters mutated cancer cells, replicates rapidly, and breaks them open.

Timeline

  1. Monday: CG Oncology announced the positive Phase 3 cretostimogene results.

Health Landscape

Oncolytic virus immunotherapies, which use engineered viruses to destroy cancer cells directly, are an emerging class of treatment for localized disease. This Phase 3 result moves cretostimogene into the late-stage evidence needed to judge its place alongside surgical removal for intermediate-risk bladder cancer.

For patients with intermediate-risk bladder cancer, a therapy that substantially lowers recurrence could reduce the need for repeated surgical procedures and help preserve bladder function over time. Patients currently face monitoring every three months after surgical removal, and any new option would be weighed against that routine.

The takeaway

Recurrence after bladder cancer surgery is a major driver of repeated procedures and long-term risk. Patients with intermediate-risk disease can ask their care teams whether emerging immunotherapies are appropriate as part of their follow-up planning.

Further reading

Explore more on Cancer treatments and research developments.